Advances in the causes and management of community acquired pneumonia in adults
- PMID: 28694251
- DOI: 10.1136/bmj.j2471
Advances in the causes and management of community acquired pneumonia in adults
Abstract
Community acquired pneumonia remains a common cause of morbidity and mortality. Usually, the causal organism is not identified and treatment remains empiric. Recent computed tomography and magnetic resonance imaging studies have challenged the accuracy of the clinical diagnosis of pneumonia, and epidemiologic studies are changing our perspective of what causes community acquired pneumonia, especially the role of viral pathogens and the frequent finding of multiple pathogens. The past decade has seen increasing overuse of empiric coverage of meticillin resistant Staphylococcus aureus and antibiotic resistant Gram negative pathogens owing to inappropriate application of guidelines for healthcare associated pneumonia. Optimal treatment remains a matter for debate, especially in very sick patients, including the role of combination antibiotic therapy and corticosteroids. Pneumonia care bundles are being defined to improve outcomes. Increased recognition of both acute and long term cardiac complications is shifting our concept of pneumonia from an acute lung disease to a multisystem problem with adverse chronic health consequences.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Conflict of interest statement
Competing interests: We have read and understood BMJ policy on declaration of interests and declare the following interests: RGW’s institution received an investigator initiated grant from bioMerieux.
Similar articles
-
Community-acquired pneumonia: what is relevant and what is not?Curr Opin Pulm Med. 2007 May;13(3):177-85. doi: 10.1097/MCP.0b013e3280f6cf02. Curr Opin Pulm Med. 2007. PMID: 17414124 Review.
-
Community-acquired pneumonia with risk for drug-resistant pathogens.South Med J. 2013 Mar;106(3):209-16. doi: 10.1097/SMJ.0b013e318287fe71. South Med J. 2013. PMID: 23462490
-
Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis.Eur Respir J. 2015 May;45(5):1353-63. doi: 10.1183/09031936.00152514. Epub 2015 Jan 22. Eur Respir J. 2015. PMID: 25614173
-
Management of community-acquired pneumonia: a review and update.Ther Adv Respir Dis. 2011 Feb;5(1):61-78. doi: 10.1177/1753465810381518. Epub 2010 Oct 8. Ther Adv Respir Dis. 2011. PMID: 20935033 Review.
-
Diagnosis and treatment of community-acquired pneumonia.Am Fam Physician. 2006 Feb 1;73(3):442-50. Am Fam Physician. 2006. PMID: 16477891 Review.
Cited by
-
Clinical and financial burden of hospitalised community-acquired pneumonia in patients with selected underlying comorbidities in England.BMJ Open Respir Res. 2020 Oct;7(1):e000703. doi: 10.1136/bmjresp-2020-000703. BMJ Open Respir Res. 2020. PMID: 33051218 Free PMC article.
-
Microbiology and Outcomes of Institutionalized Patients With Stroke-Associated Pneumonia: An Observational Cohort Study.Front Microbiol. 2021 Dec 3;12:720051. doi: 10.3389/fmicb.2021.720051. eCollection 2021. Front Microbiol. 2021. PMID: 34925251 Free PMC article.
-
Neural architecture search for pneumonia diagnosis from chest X-rays.Sci Rep. 2022 Jul 4;12(1):11309. doi: 10.1038/s41598-022-15341-0. Sci Rep. 2022. PMID: 35788644 Free PMC article.
-
Omadacycline: a novel aminomethylcycline.Infect Drug Resist. 2019 Jul 2;12:1895-1915. doi: 10.2147/IDR.S171352. eCollection 2019. Infect Drug Resist. 2019. PMID: 31308710 Free PMC article. Review.
-
Investigational and Experimental Drugs for Community-Acquired Pneumonia: the Current Evidence.J Exp Pharmacol. 2020 Nov 19;12:529-538. doi: 10.2147/JEP.S259286. eCollection 2020. J Exp Pharmacol. 2020. PMID: 33239925 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous